Skip to content
Screener

Beta Bionics BBNX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Insulet logo
InsuletPODD
$290.8M-7.7%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$32.61M+88.0%
Embecta Corp. logo
Embecta Corp.EMBC
$156M-18.1%
Medtronic logo
MedtronicMDT
AdaptHealth logo
AdaptHealthAHCO

Other financials

Income statement

See full
Revenue$32.0M+37.8%
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
CapEx$1.0M-41.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$737.83M+18.7%
Enterprise value$700.02M+18.0%
P/S6.2×-1.8×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Return on equity-26.2%
Debt / equity0.0×
Current ratio8.9×-5.8×

Where this comes from

Reported directly by Beta Bionics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777
Line itemJune 30,2026December 31,2025
Property and equipment, net10,7488,600
Operating lease right-of-use asset5,8166,627
Long-term investments44,64845,431
Other long-term assets141180
Total assets$292,387$328,743
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$5,351$4,998

Item 1. Financial Statements.

FAQ

What is Beta Bionics's deferred tax assets and other non-current assets?
Beta Bionics (BBNX) reported deferred tax assets and other non-current assets of $141K in Q2 2026.
How has Beta Bionics's deferred tax assets and other non-current assets changed year-over-year?
Beta Bionics's deferred tax assets and other non-current assets decreased by 2.1% year-over-year, from $144K to $141K.
What is the long-term trend for Beta Bionics's deferred tax assets and other non-current assets?
Over 2 years (2023 to 2025), Beta Bionics's deferred tax assets and other non-current assets has grown at a 22.0% compound annual growth rate (CAGR), from $121K to $180K.

Ask your AI about Beta Bionics's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude